Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis.

Giorgio Walter CanonicaFrancesco BlasiNunzio CrimiPierluigi PaggiaroAlberto PapiFrancesca FanelliAnnalisa StassaldiFelicetto Ferrara

Published in: Clinical and molecular allergy : CMA (2021)

There is a strong rationale for testing all asthma biomarkers during diagnosis and disease follow-up. Given the large availability and the limited costs, these tests are cost-effective tools to detect severe Type 2 asthma, stratify patients by phenotype, and drive appropriate treatment decisions.

Keyphrases

end stage renal disease
chronic obstructive pulmonary disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
lung function
prognostic factors
cystic fibrosis
combination therapy
patient reported
replacement therapy